Replies to post #67166 on Biotech Values

[genisi]

...And the very same trial was suspended after a patient (one of the next 40 enrolled for safety) had rebleeding:

Omrix Biopharmaceuticals Provides Update On Fibrin Pad U.S. Phase II Clinical Trial In Mild to Moderate Bleeding

http://www.biocetera.com/inthenews.php?id=105054

NEW YORK--(BUSINESS WIRE)--Omrix Biopharmaceuticals, Inc. (“Omrix”) (NASDAQ: OMRI - News), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that the Fibrin Pad U.S. Phase II clinical trial in mild to moderate bleeding was suspended yesterday afternoon to investigate an incident of post-operative bleeding. The Company will provide an update once additional information is available.

About the Fibrin Pad